Area of research
Molecular Biology · Surgery
Research interest
Research focused on DNA and Cancer research, with related work in Gemcitabine, Phosphodiesterase, Pancreatic ductal adenocarcinoma. Notable publications include 'The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors', 'Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target', and 'DNA topoisomerase-targeting chemotherapeutics: what’s new?'.
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine
N-terminal domain of tyrosyl-DNA phosphodiesterase I regulates topoisomerase I-induced toxicity in cells
Sulfotransferase 4A1 activity facilitates sulfate-dependent cellular protection to oxidative stress
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts
Sphingolipid metabolism and drug resistance in ovarian cancer
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer
DNA topoisomerase-targeting chemotherapeutics: what’s new?
JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin
Tyrosyl-DNA Phosphodiesterase I Catalytic Mutants Reveal an Alternative Nucleophile That Can Catalyze Substrate Cleavage
Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target
ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin